Plasminogen activator inhibitor-1 and HbA1c defined prediabetes: The Guangzhou Biobank Cohort Study-CVD

Clinical Endocrinology

Volumn 74, Issue 4, 2011, Pages 528-531

  Xu, Lin ^a,b   Jiang, Chao Qiang ^b   Lam, Tai Hing ^a   Bao, Bei ^b   Cheng, Kar Keung ^c   Thomas, G Neil ^c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b Guangzhou No 12 Hospital   (China)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MITOGEN ACTIVATED PROTEIN KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HONG KONG; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL;

FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDIABETIC STATE;

EID: 79952437473     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2010.03948.x     Document Type: Article

References (16)

1. Davidson, M., Zhu, J., Lu, W., et al. (2006) Plasminogen activator inhibitor-1 and the risk of Type 2 diabetes mellitus in American Indians: the Strong Heart Study. Diabetic Medicine, 23, 1158-1159. (Pubitemid 44401150)
2. Festa, A., D'Agostino Jr, R., Tracy, R.P., et al. (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes, 51, 1131-1137. (Pubitemid 34438360)
3. Nagi, D.K., Mohamed Ali, V., Jain, S.K., et al. (1996) Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians. Diabetic Medicine, 13, 59-64. (Pubitemid 26046597)
4. American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care, 33 (Suppl 1), S62-S69.
5. Xu, L., Jiang, C.Q., Lam, T.H., et al. (2010) Brachial-ankle pulse wave velocity and cardiovascular risk factors in the non-diabetic and newly diagnosed diabetic Chinese: Guangzhou Biobank Cohort Study-CVD. Diabetes/Metabolism Research and Reviews, 26, 133-139.
6. Jiang, C., Thomas, G.N., Lam, T.H., et al. (2006) Cohort profile: The Guangzhou Biobank Cohort Study, a Guangzhou-Hong Kong-Birmingham collaboration. International Journal of Epidemiology, 35, 844-852. (Pubitemid 44540731)
7. Jiang, C.Q., Lam, T.H., Lin, J.M., et al. (2010) An overview of the Guangzhou biobank cohort study-cardiovascular disease subcohort (GBCS-CVD): a platform for multidisciplinary collaboration. Journal of Human Hypertension, 24, 139-150.
8. Xu, L., Jiang, C.Q., Lam, T.H., et al. (2010) Impact of impaired fasting glucose and impaired glucose tolerance on arterial stiffness in an older Chinese population: the Guangzhou Biobank Cohort Study-CVD. Metabolism, 59, 367-372.
9. Samad, F., &, Loskutoff, D.J., (1996) Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Molecular Medicine, 2, 568-582. (Pubitemid 26353106)
10. Juhan-Vague, I., &, Alessi, M.C., (1993) Plasminogen activator inhibitor 1 and atherothrombosis. Thrombosis and Haemostasis, 70, 138-143. (Pubitemid 23225466)
11. De Taeye, B., Smith, L.H., &, Vaughan, D.E., (2005) Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Current Opinion in Pharmacology, 5, 149-154. (Pubitemid 40378745)
12. Thogersen, A.M., Jansson, J.H., Boman, K., et al. (1998) High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation, 98, 2241-2247. (Pubitemid 28533841)
13. Alessi, M.C., Peiretti, F., Morange, P., et al. (1997) Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes, 46, 860-867. (Pubitemid 27188265)
14. Vague, P., Juhan-Vague, I., Chabert, V., et al. (1989) Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. Metabolism, 38, 913-915. (Pubitemid 19229973)
15. Eliasson, M.C., Jansson, J.H., Lindahl, B., et al. (2003) High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA study. Cardiovascular Diabetology, 2, 19.
16. Lyon, C.J., &, Hsueh, W.A., (2003) Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. American Journal of Medicine, 115 (Suppl 8A), 62S-68S.